Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review.
JACC CardioOncol
; 4(1): 1-18, 2022 Mar.
Article
in En
| MEDLINE
| ID: mdl-35492830
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; BRAF inhibitor; BRAF, rapidly accelerated fibrosarcoma B-type; CVAE, cardiovascular adverse event; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; LVSD, left ventricular systolic dysfunction; MEK inhibitor; MEK, mitogen-activated extracellular signal-regulated kinase; RAF, rapidly accelerated fibrosarcoma; VEGF, vascular endothelial growth factor; cardio-oncology; cardiovascular toxicity; hypertension; left ventricular systolic dysfunction; melanoma
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
JACC CardioOncol
Year:
2022
Document type:
Article
Affiliation country:
United kingdom